Provided by Tiger Fintech (Singapore) Pte. Ltd.

Unity Biotechnology

1.01
+0.0000
Volume:11.14K
Turnover:11.06K
Market Cap:17.38M
PE:-0.62
High:1.01
Open:0.9927
Low:0.9863
Close:1.01
Loading ...

Company Profile

Company Name:
Unity Biotechnology
Exchange:
NASDAQ
Establishment Date:
2009
Employees:
16
Office Location:
285 East Grand Avenue,South San Francisco,California,United States
Zip Code:
94080
Fax:
- -
Introduction:
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

Directors

Name
Position
Anirvan Ghosh
Chief Executive Officer and Director
Keith R. Leonard Jr.
Chairman and Director
Camille D. Samuels
Director
Gilmore O'Neill
Director
Graham K. Cooper
Director
Kristina M. Burow
Director
Margo R. Roberts
Director
Nathaniel E. David
Director
Paul L. Berns
Director

Shareholders

Name
Position
Anirvan Ghosh
Chief Executive Officer and Director
Lynne Sullivan
Chief Financial Officer and Head of Corporate Development
Alexander Nguyen
General Counsel and Corporate Secretary
Jamie Dananberg
Chief Medical Officer